ANEB Anebulo Pharmaceuticals, Inc.

38

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price
$2.76
Decreased by -7.69%
Dollar Volume
21.47 K
ADR%
11.54
Earnings Report Date (estimate)
Nov 10, 22 (N/A)
Market Cap.
70.75 M
Shares Float
2.93 M
Shares Outstanding
25.63 M
Beta
0.00
Price / Earnings
-1.78
BPR
114.61
20D Range
2.24 3.43
50D Range
2.16 3.49
200D Range
1.77 7.00
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.11
Increased by +93.08%
 -0.10
Decreased by -10.00%
Sep 9, 22 -0.10
Increased by +85.51%
 -0.07
Decreased by -42.86%
May 11, 22 -0.08 -0.05
Decreased by -60.00%
Feb 11, 22 -0.05 -0.06
Increased by +16.67%
Sep 22, 21 -1.59 -0.03
Decreased by -5.20 K%
Jun 21, 21 -0.69 -0.04
Decreased by -1.62 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
 -2.61 M
Decreased by -68.14%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -2.32 M
Increased by +92.02%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -1.88 M
Decreased by -237.60%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
 -1.07 M
Decreased by -226.53%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
 -1.55 M
Decreased by -505.90%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00 - -29.11 M -
Decreased by N/A%
-
Mar 31, 21 0.00 - -555.83 K -
Decreased by N/A%
-
Dec 31, 20 0.00 - -328.60 K -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.